about
Therapeutic drug monitoring and pharmacogenetic study of HIV-infected ethnic Chinese receiving efavirenz-containing antiretroviral therapy with or without rifampicin-based anti-tuberculous therapyMulticenter study of trimethoprim/sulfamethoxazole-related hepatotoxicity: incidence and associated factors among HIV-infected patients treated for Pneumocystis jirovecii pneumoniaCholelithiasis and Nephrolithiasis in HIV-Positive Patients in the Era of Combination Antiretroviral TherapyPresence of Tablet Remnants of Nevirapine Extended-Release in Stools and Its Impact on Virological Outcome in HIV-1-Infected Patients: A Prospective Cohort StudySheltering effect and indirect pathogenesis of carbapenem-resistant Acinetobacter baumannii in polymicrobial infection.Use of Hypoprothrombinemia-Inducing Cephalosporins and the Risk of Hemorrhagic Events: A Nationwide Nested Case-Control Study.Impact of mecA gene testing and intervention by infectious disease clinical pharmacists on time to optimal antimicrobial therapy for Staphylococcus aureus bacteremia at a University HospitalAn on-spot internal standard addition approach for accurately determining colistin A and colistin B in dried blood spots using ultra high-performance liquid chromatography-tandem mass spectrometry.Kidney dysfunction associated with tenofovir exposure in human immunodeficiency virus-1-infected Taiwanese patients.Development and validation of a high-performance liquid chromatography-fluorescence detection method for the accurate quantification of colistin in human plasma.Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.Do we still need lead-in dosing of nevirapine in HIV-infected patients who are receiving rifampicin-containing antituberculous therapy?Effectiveness of education programs about oral antibiotic suspensions in pediatric outpatient services.Simultaneous quantification of antimicrobial agents for multidrug-resistant bacterial infections in human plasma by ultra-high-pressure liquid chromatography-tandem mass spectrometry.Nemonoxacin (TG-873870) for treatment of community-acquired pneumonia.Development and application of a comparative fatty acid analysis method to investigate voriconazole-induced hepatotoxicity.The ratio of pre-dialysis vancomycin trough serum concentration to minimum inhibitory concentration is associated with treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.Safety of high-dose daptomycin in patients with severe renal impairment.Progress of pharmacist collaborative practice: status of state laws and regulations and perceived impact of collaborative practiceSurvey of pharmacist collaborative drug therapy management in hospitalsRapid and sensitive determination of posaconazole in patient plasma by capillary electrophoresis with field-amplified sample stackingMetabolomics Investigation of Voriconazole-Induced Hepatotoxicity in MiceAugmented renal clearance is associated with inadequate antibiotic pharmacokinetic/pharmacodynamic target in Asian ICU population: a prospective observational study
P50
Q28539806-DBBDB9ED-2DAC-4E23-BFAD-FB5F84218DABQ28542714-F089FADA-57D5-45EB-B946-4472768A88EBQ28547869-A9DE4076-6F41-4A98-815D-8BEA270CAFCFQ28550278-B004DEBA-1074-4101-8767-BA6133A1239DQ33798228-D949D7EE-FBDF-4A56-938F-4DE8FCCCDDCAQ36087215-B29D87E7-3888-4468-9AE8-1C14E1434FCDQ36747609-8E9FB9EF-240E-4AFD-99CB-7A5A16817319Q40079058-DA975403-B346-4AC2-B77F-91B342EE92D4Q40378082-6091281A-0124-41C2-A3FC-73225569F006Q41544691-CAB65696-ADFA-40AB-9FF2-73E43ABF6551Q41702416-F3064AE5-F83F-40E2-B85E-386B9FDD6DC6Q43262562-7AB800DD-21CF-4147-A4A1-AB59AD22C55CQ44184364-77E0428D-C62D-4611-9D8E-4FF2405E9A81Q45949963-BAB7F67C-1758-4CFB-8807-8B7262E14590Q46887329-E662E626-75E4-4D56-9FB5-795DA44FF830Q53466711-BCAF62B5-350E-442B-989A-8BB64A75C76EQ53704626-F10BD90B-0A97-4E2A-84AD-1EAFD9138D98Q54120294-CA049390-DDFE-4849-AD09-33B4325104E9Q73893475-AE14A533-683F-4415-8C53-DE22330654B5Q79422292-E036752E-C134-449E-819D-42F74FCBF699Q84840306-60E432F5-1D68-44FA-9C69-641468EDBE22Q92613217-D54C60B9-4795-433C-8C5B-86C4E319130DQ93185288-4E5EB2ED-58F7-4917-B48E-20943EB88C60
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Shu-Wen Lin
@ast
Shu-Wen Lin
@en
Shu-Wen Lin
@es
Shu-Wen Lin
@nl
type
label
Shu-Wen Lin
@ast
Shu-Wen Lin
@en
Shu-Wen Lin
@es
Shu-Wen Lin
@nl
prefLabel
Shu-Wen Lin
@ast
Shu-Wen Lin
@en
Shu-Wen Lin
@es
Shu-Wen Lin
@nl
P106
P1153
55628178800
P31
P496
0000-0002-9940-0850